Patents by Inventor Andrew K. Godwin

Andrew K. Godwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXTRACELLULAR VESICLE PROTEOMIC BIOMARKER PANEL FOR OVARIAN CANCER SCREENING AND THE EARLY DETECTION OF DISEASE
    Publication number: 20240026463
    Abstract: A method of reporting a diagnoses of cancer in a subject is provided. The method can include obtaining a biological sample from the subject, and measuring a presence or amount of a combination of biomarkers in the biological sample. The combination of biomarkers includes ACSL4, IGSF8, ITGA2, ITGA5, ITGB3, and MYOF, and optionally STX4 and/or optionally FOLR1. The presence of the biomarkers in the sample indicates the presence of cancer cells in the subject, and/or an increased amount of the biomarkers in the sample indicates presence of cancer cells in the subject. The method can include determining whether the presence or amount of the combination of biomarkers indicates the presence of cancer cells in the subject, and then preparing a report on the presence of cancer cells in the subject.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventors: Camille V. Trinidad, Harsh B. Pathak, Mihaela Sardiu, Andrew K. Godwin
  • GENE EXPRESSION SIGNATURES ASSOCIATED WITH RESPONSE TO IMATINIB MESYLATE IN GASTROINTESTINAL STROMAL TUMORS AND USE THEREOF FOR PREDICTING PATIENT RESPONSE TO THERAPY AND IDENTIFICATION OF AGENTS WHICH HAVE EFFICACY FOR THE TREATMENT OF CANCER
    Publication number: 20150080252
    Abstract: Compositions and methods are disclosed for identifying agents useful for the treatment of malignancy, particularly GISTs which are resistant to imatinib mesylate (IM). In a preferred embodiment, agents which sensitize cancer cells to IM are provided.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 19, 2015
    Inventors: Andrew K. Godwin, Burton Eisenberg, Yuliya Skorobogatko, Lori Rink, Andrew Kossenkov, Michael F. Ochs
  • GENE EXPRESSION SIGNATURES ASSOCIATED WITH RESPONSE TO IMATINIB MESYLATE IN GASTROINTESTINAL STROMAL TUMORS AND USE THEREOF FOR PREDICTING PATIENT RESPONSE TO THERAPY AND IDENTIFICATION OF AGENTS WHICH HAVE EFFICACY FOR THE TREATMENT OF CANCER
    Publication number: 20130058992
    Abstract: Compositions and methods are disclosed for identifying agents useful for the treatment of malignancy, particularly GISTs which are resistant to imatinib mesylate (IM). In a preferred embodiment, agents which sensitize cancer cells to IM are provided.
    Type: Application
    Filed: April 21, 2010
    Publication date: March 7, 2013
    Inventors: Andrew K. Godwin, Burton Eisenberg, Yuliya Skorobogatko, Lori Rink, Andrew Kossenkov, Michael F. Ochs
  • Antibodies specific for OVCA DNA encoded proteins and methods for their use
    Patent number: 5821338
    Abstract: This invention provides a novel gene, OVCA1, isolated from human chromosome 17p13.3. Disruption of the OVCA1 gene is associated with cellular proliferation and tumor development. The OVCA1 gene, along with its encoded protein and antibodies thereto, provides a biological marker for early diagnosis of metastatic disease. The gene also will be useful in gene replacement therapy for treating various forms of cancer.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: October 13, 1998
    Assignee: Fox Chase Cancer Center
    Inventor: Andrew K. Godwin
  • Gene associated with suppression of tumor development
    Patent number: 5801041
    Abstract: This invention provides a novel gene, OVCA1, isolated from human chromosome 17p13.3. Disruption of the OVCA1 gene is associated with cellular proliferation and tumor development. The OVCA1 gene, along with its encoded protein and antibodies thereto, provides a biological marker for early diagnosis of metastatic disease. The gene also will be useful in gene replacement therapy for treating various forms of cancer.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: September 1, 1998
    Assignee: Fox Chase Cancer Center
    Inventor: Andrew K. Godwin